DePuy prices flotation in the middle of estimated range
This article was originally published in Clinica
Orthopaedics company DePuy has priced its initial public offering on the New York Stock Exchange at $17.50 a share, in the middle of the price range assumed in the prospectus. Of the 14.8 million shares offered, representing 15% of DePuy, 7.8 million were issued by the company and 7.0 million by its parent Corange, which also owns German diagnostics company Boehringer Mannheim.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.